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99Developing Therapies for Heart Failure With Preserved Ejection FractionCurrent State and Future DirectionsThe burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To
date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The
pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and
pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our
understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with
development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included
representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings
from this meeting. (J Am Coll Cardiol HF 2014;2:97–112) ª 2014 by the American College of Cardiology
FoundationEpidemiologic studies suggest that the prevalence and
hospitalizations related to heart failure with preserved
ejection fraction (HFpEF) is rising (1), and the growing
elderly population guarantees further worsening of these
trends. To date, there are no approved therapies to reduce
hospitalization or mortality for HFpEF. There remains a
lack of consensus on the basic pathophysiology and deﬁ-
nition, classiﬁcation, therapeutic targets, and goals for
therapy for this syndrome. To facilitate consensus for the
next steps in developing therapies for HFpEF, the Food
and Drug Administration hosted a meeting on February 6,
2013, that was attended by representatives from academia,
industry, and the regulatory agencies from the United
States and Europe. This meeting was not industry spon-
sored. This document represents the proceedings from this
meeting.
Importance
Considering its prevalence and outcomes, future projections,
and lack of effective therapies, HFpEF represents the single
largest unmet need in cardiovascular medicine.
Epidemiology. Table 1 summarizes the epidemiology of
HFpEF and the difference in prevalence and outcomes
based on the deﬁnitions used and the population studied
(1–7). Hospitalizations for HFpEF have increased over
time, whereas those for heart failure with reduced ejection
fraction (HFrEF) have declined. These patients have longer
length of stay and are more likely to require skilled nursing
care (1). Mortality in outpatient cohorts appears to be lower
for HFpEF than HFrEF (8), but data are inconsistent for
in-hospital mortality (5,6). Observational studies show a
higher mortality for HFpEF than clinical trials (9). The
combined mortality and readmission rates at 60 to 90 days
post-discharge are comparable for HFrEF (36.1%) and
HFpEF (35.3%) (7). In the I-PRESERVE (Irbesartan in
Heart Failure With Preserved Systolic Function) and the
CHARM (Candesartan in Heart Failure-Assessment of
Reduction in Mortality and Morbidity) trials, 70% of mor-
tality in HFpEF was cardiovascular (8,10), whereas in
HFrEF, cardiovascular causes accounted for 83% of deaths(8). Exercise capacity and quality of life are similarly reduced
in HFpEF and HFrEF (11,12).
Summary of clinical trials in HFpEF. No speciﬁc treat-
ment for HFpEF is established, and management is limited
to diuretics and treatment of comorbidities. Angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers were not effective in reducing mortality (13–19) (see
also Table 2 [13–30]). Digoxin had no effect on mortality in
either HFrEF or HFpEF, but had similar beneﬁts on the
composite of hospitalizations or death due to worsening HF
regardless of EF (25). b-blockers have not shown beneﬁts in
HFpEF (14,22,23,29,30). Therapy with spironolactone (27)
showed improvement in diastolic function and hypertrophy
but not in clinical outcomes, which may be related to inclu-
sion of relatively stable patients. Sildenaﬁl (28) showed no
improvement in exercise capacity, quality of life, or clinical
status in HFpEF. The PARAMOUNT (Prospective Com-
parison of Angiotensin Receptor Neprilysin Inhibitor with
Angiotensin Receptor Blockers on Management of HFpEF)
trial (31) showed favorable effects of angiotensin receptor
neprilysin inhibitor on natriuretic peptides and left atrial (LA)
volumes, and a phase III trial with this agent is ongoing.
Exercise training in HFpEF has been shown to improve
symptoms and quality of life (32–37).
Clinical Variants
Although there are common comorbidity proﬁles among
patients with HFpEF, speciﬁc underlying etiologies are only
seen in a small proportion of patients. The vast majority of
patients do not have any known speciﬁc genetic, pericardial,
myocardial, or valvular etiology. The most urgent need is to
develop therapies targeting this majority of HFpEF patients;
however, future trials will beneﬁt from enhanced phenotypic
characterization and categorization that may allow improved
targeting of experimental therapies.
There are several speciﬁc etiologies of HFpEF (e.g.,
hypertrophic cardiomyopathy) but the vast majority does not
have a speciﬁc underlying primary cardiac cause. Better
understanding of the pathophysiologic pathways may allow
identiﬁcation of better therapeutic targets. Studies suggest
Table 1 Epidemiology of H
First Author (Ref. #) (Trial)
Cohort studies
Vasan et al. (3)
(FHS)
Owan et al. (5)
(Olmsted County)
4
Bhatia et al. (6)
(Ontario)
2
Steinberg et al. (1)
(GWGL-HF)
11
Registries
Philbin et al. (2)
(MISCHF)
1
Fonarow et al. (7)
(OPTIMIZE-HF)
4
Yancy et al. (4)
ADHERE
5
ADHERE ¼ Acute Decompensated Heart F
HHF ¼ hospitalized heart failure; MISCHF ¼
Heart Failure.
Abbreviations
and Acronyms
EF = ejection fraction
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
LV = left ventricular
LA = left atrial
NP = natriuretic peptide
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100that HFpEF is a heterogeneous
entity, and careful phenotyping
is needed to target the right
population for understanding the
pathophysiology and response to
treatments (38–40). Most patients
have 1 or more comorbidities that
may worsen HFpEF. Neverthe-
less, many of these patients do
not have any yet identiﬁed spe-
ciﬁc primary cardiac pathology.
Understanding the basic disease
process and targeting novel ther-apies to this vast majority of typical HFpEF patients is ur-
gently needed.Pathophysiology
The pathophysiology of HFpEF is incompletely understood.
There are no animal models ideally suitable for drug testing.
Changes leading to hospitalization and the differences
between hospitalized versus outpatients are incompletely
understood. Future research should focus on understanding
the basic and clinical mechanisms of HFpEF.
The pathophysiology of HFpEF is complex, incompletely
understood, and related to cardiac structural and functional
alterations, and systemic and pulmonary vascular abnor-
malities, which, coupled with extra-cardiac causes of volume
overload (e.g., kidney disease), can lead to the signs and
symptoms of HF.F With Preserved EF
Population Prevalence and EF
73 outpatients 51%, EF 50%
,596 HHF patients 47%, EF 50%
,802 HHF patients 31%, EF 50% 13%,
40%  EF <50%
0,621 HHF patients 36%, EF 50% 14%,
40%  EF <50%
,291 HHF patients 24%, EF 50% 18%,
40%  EF <50%
1,267 HHF patients 51.2%, EF 40% 34.6%,
40%  EF <50% 47.6
EF >50%
2,187 HHF patients 50.4%, EF 40%
ailure National Registry; EF ¼ ejection fraction; FHS ¼ Fram
Management to Improve Survival in Congestive Heart FailurLeft ventricle. Left ventricular (LV) abnormalities in
HFpEF are varied and compounded by abnormal ventricular-
arterial coupling, poor vasodilator reserve, chronotropic
incompetence, coronary disease, microvascular dysfunction,
and right ventricular dysfunction with or without coexisting
pulmonary vascular disease.
STRUCTURAL CHANGES. LV size is normal or near normal in
most patients with HFpEF. Most patients have increased
LV mass or relative wall thickness, and may have concentric
remodeling or hypertrophy. In 1 study, mean LV mass index
was 102  29 g/m2; 27% of patients had concentric LV
remodeling, 26% had concentric LV hypertrophy, and 16%
had eccentric LV hypertrophy in HFpEF (41). Changes in
myocyte structure (42) with increased diameter in HFpEF
than HFrEF have been reported.
DIASTOLIC FUNCTION. Diastolic dysfunction in HFpEF can
result from increased LV stiffness from hypertrophy and
interstitial ﬁbrosis, as well as from abnormal LV relaxation
due to abnormal calcium cycling. Titin functions as a bidi-
rectional spring responsible for early diastolic recoil and
late diastolic distensibility, regulates diastolic function.
Alterations in titin phosphorylation cause diastolic dysfunc-
tion, suggesting that titin may be a therapeutic target (43,44).
Abnormal myocardial energetics in HFpEF can impact
relaxation and ﬁlling. Ischemia and microvascular dysfunc-
tion are associated with changes in intracellular calcium and
are related to HFpEF. Diastolic dysfunction results in inef-
fective LA emptying and LV ﬁlling, and reduced ability to
augment cardiac output with exercise, increases in pulmonaryMortality Readmission
Annual during median 6.2 yrs: 8.7%
1 yr: 29%
5 yrs: 65%
30 days: 5.3
1 yr: 22.2%
30 days: 4.5, EF 50%
1 yr: 13.5%, EF 50%
In-hospital: 2.5%, EF 50%
2.3%, 40%  EF <50%
In-hospital: 3.0%, EF >50% 5.0%,
40%  EF <50%;
6 months: 14.0%, EF >50%
15.0%, 40%  EF <50%
%,
In-hospital: 2.9%, EF 40% 3.0%,
40%  EF <50%
2.9%, EF >50%
60–90 days: 9.5%, EF 40% 9.2%,
40%  EF <50%
9.3%, EF >50%
60–90 days: 29.2%, EF 40%
29.0%, 40%  EF <50%
30.9%, EF >50%
In-hospital: 2.8%, EF 40%
ingham Heart Study; GWGL-HF ¼ Get With the Guidelines – Heart Failure; HF ¼ heart failure;
e; OPTIMIZE-HF ¼ Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with
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101pressure, and resulting in symptoms and ﬂuid retention.
HFpEF patients have increased LV stiffness (41) with
increased passive elastance. Echocardiography can describe
impaired relaxation using longitudinal mitral annular early
diastolic tissue velocity (e’), and increased LV ﬁlling pressures
via the ratio of early mitral inﬂow (E) to e’ (i.e., E/e’ ratio).
Measurement of chamber compliance requires analysis of the
end-diastolic pressure volume relationship, which is shifted
upward and leftward in HFpEF. Assessment of diastolic
function and ﬁlling pressures during exercise has emerged as
a useful tool (45). Left bundle branch block deteriorates
diastolic dysfunction with increased E/e’, LA diameter, and
reduced deceleration and isovolumic relaxation time (46).
SYSTOLIC FUNCTION. Although LVEF is preserved and
some patients may even have normal-appearing LV size and
geometry, systolic function may be abnormal in HFpEF,
including an increase in end-systolic elastance (47). How-
ever, when normalized for remodeling, the end-systolic
elastance/volume to mass ratio is normal. The increases in
end-systolic elastance and effective arterial elastance may
contribute to decreased exercise capacity due to limited
ability to increase both above baseline. In HFpEF, longi-
tudinal strain is typically reduced whereas radial strain is
preserved, resulting in preservation of LVEF despite longi-
tudinal systolic dysfunction (48). Systolic reserve during
exercise is also impaired in HFpEF (38).
INTERSTITIAL MATRIX. Diffuse myocardial ﬁbrosis maybe a
mediator or a modiﬁer of HFpEF. Myocytes embedded in
ﬁbrotic tissue are prone to energy starvation as ﬁbrosis affects
capillary blood supply by interposing collagen and by peri-
vascular collagen limiting vasomotor reserve. Diffuse ﬁbrosis
is linked with diastolic dysfunction, vasomotor dysfunction,
arrhythmias, and mortality (49). Experimental models have
produced HF by creating diffuse ﬁbrosis from cardiac
ﬁbroblast activation (50), suggesting a primary role for ﬁb-
roblast activity.
Left atrium. HFpEF patients may have ineffective LA
emptying, increased size, and abnormal function. In the
CHARM-Preserved study (Candesartan Cilexetil in Heart
Failure Assessment of Reduction in Mortality and Mor-
bidity), LA volume index was >32 ml/m2 in 71% of the
patients (51), and in the I-PRESERVE echocardiographic
substudy, 66% of patients had LA enlargement (52). The LA
size is a predictor of outcomes (52). Recruitment of LA
contractility during stress is impaired in HFpEF and may
contribute to the transition from asymptomatic state to overt
HFpEF (53).
Endothelial function and arterial stiffness. Endothelial
function and nitric oxide inﬂuences arterial stiffness in
HFpEF and arterial stiffness increases with hypertension.
Arterial distending pressure leads to recruitment of inelastic
collagen ﬁbers (54). Age and cardio-metabolic abnormalities
are related to arterial stiffness, which in turn is associated
with HFpEF. Increases in LV end-systolic and arterial
elastance occur with aging, particularly in women, and mayresult in ventricular-vascular stiffening leading to HFpEF
(55). Pulse wave velocity is higher (56) and venous capaci-
tance lower in HFpEF than in HFrEF, explaining why
these patients are more sensitive to vasodilators and diuretics
(47). Worsening vascular failure is proposed as a precipitant
for hospitalization in HFpEF, but few data are available.
HFpEF patients have limited vasodilatory response to
exercise. Endothelial dysfunction in HFpEF is associated
with adverse outcomes (57) and it also affects microvascu-
lature that in turn may modulate diastolic function via
paracrine effects (58).
Pulmonary hypertension. Increased LV stiffness augments
end-diastolic pressure (59), leading to increased pulmonary
venous pressure and a passive increase in pulmonary artery
pressure. Chronically elevated pressures induce a reactive
component (60), and the transpulmonary gradient increases
out of proportion to the wedge pressure, leading to a higher
mean pressures than expected. Pulmonary vasculopathy
similar to HFrEF can be postulated in HFpEF, but has not
yet been shown.
Right ventricle. The right ventricle better tolerates volume
than pressure (61), leading to high prevalence of dysfunction
when pulmonary hypertension develops. Right ventricular
dysfunction worsens prognosis and is related to the trans-
mission of elevated LV ﬁlling pressures to the pulmonary
bed. The chronic elevated pulmonary pressure leads to right
ventricular hypertrophy and later, to contractile dysfunction,
tricuspid regurgitation, and diminished cardiac output.
Subendocardial right ventricular dysfunction in HFpEF has
been shown (62).
Animal models. A few animal models of HFpEF have
been described, but they mimic some but not all of the
characteristics described in humans with HFpEF, signiﬁ-
cantly limiting their usefulness for testing novel therapies.
Development of better animal models, especially large ani-
mal models that mimic human disease more closely, may be
useful in drug testing in future. However, until that time, the
lack of animal models should not prevent human testing of
promising therapies.
Comorbidities
HFpEF patients usually have multiple comorbid conditions,
the treatment of which may improve outcomes.
Comorbidities are highly prevalent in these patients and
are related to ventricular-vascular dysfunction and prognosis
(63). Hypertension affects the risk of developing HFpEF
and treatment substantially lowers this risk. Obesity, anemia,
diabetes, and renal dysfunction are associated with unique
ventricular-vascular characteristics contributing to HFpEF;
however, changes seen in HFpEF cannot be accounted for
by these comorbidities alone (64). Subclinical lung disease is
related to HFpEF (65). The exact role of sleep apnea in
HFpEF needs further study. Atrial ﬁbrillation is prognos-
tically important in HFpEF (66). Comorbidity burden in-
creases hospitalization risk in HFpEF, with more non-HF
Table 2 Clinical Trials in Patients With Heart Failure and Preserved Ejection Fraction
First Author (Ref. #)
Drug
Duration
(months) n
Systolic
Function
Diastolic Function
as Inclusion Criterion Positive Outcomes
Mortality/
Readmission
Medication Trials
Setaro et al. (20)
Verapamil
1.25 40 LVEF >45% Peak ﬁlling rate <2.5 edv/s Improved clinical status Increased exercise time and diastolic ﬁlling rate
Aronow and Kronzon (13)
Enalapril
3 21 LVEF >50% Not determined Improved clinical status Increased exercise time Decreased LV mass/increased
E/A ratio
Aronow et al. (14)
Propanolol þ ACEI
12 158 LVEF 40% Not determined Reduced mortality: 30% and combined mortality þ nonfatal MI
Increased LVEF: reduced LV mass
1 yr: 65.8%
Hung et al. (21)
Verapamil
3 30 LVEF >50% Not determined Improved clinical status
Increased exercise time
Increased mitral A wave duration/pulmonary venous atrial systolic reversal
duration and isovolumic relaxation
Nodari et al. (22)
Nebivolol versus
atenolol
6 26 LVEF 50%,
LVEDD <60 mm
or <32 mm/m2
E/A <1.0 and PCWP
rest >12 mm Hg or
exercise >20 mm Hg
Nebivolol: Improved exercise capacity (VO2peak; VO2AT; VE/VCO2). Decreased
LVED posterior wall thickness. Decreased mPAP and PCWP at rest and
exercise.
Both: reduced LV mass. Increased E/A. Decreased LVED septal wall thickness
Yusuf et al. (15)
Candesartan
36.6
(median)
3,023 LVEF >40% Not determined Reduction in CV deathþHF-hospitalization
Fewer recurrent HF-hospitalizations
Median 36.6
months:
11.3%/17.1%
(for HF)
Bergström et al. (23)
Carvedilol
6 97 LVEF >45%,
LVWMI 1.2
E/A < ARRV or IVRT > ARRV;
E/A normal plus PVS/DV
< ARRV or PVARD-MAD >20 ms
or PVARV > ARRV
Increased E/A
Mottram et al. (24)
Spironolactone
6 30 LVEF >50% E/A <1
DT >250 m/s
Increased SR and peak systolic strain
Decreased LA area and PVARV
Ahmed et al. (25)
Digoxin
37
(mean)
988 LVEF >45% Not determined No long-term effect on mortality or HF-hospitalization Mean 37
months:
23.4%/20%
(for HF)
Cleland et al. (16)
Perindopril
25.2 850 LVEF >40%,
LVWMI 1.4–1.6
LAD >25 mm/m2 or
>40 mm; LVWT 12 mm,
IVRT >105 ms, E/A <0.5,
DT >280 ms
Reduced mortality þ HF-hospitalization
trend at 1 yr
Reduced HF-hospitalization at 1 yr
Improved NYHA functional class
at 1 yr and 6MWT at 1 yr
1yr: 13.1%
combined
mortality þ
HF admission
10.2% HF
admission
Massie et al. (17)
Irbesartan
49.5 4,128 LVEF 45% LVH and LAD >46 mm in men
and 42 mm in women
None Mean 49.5
months:
36.5%
combined
mortality þ
CV admission
Yip et al. (18)
Ramipril versus
irbesartan
12 151 LVEF >45% Not determined Short term increased Em and Sm
Decreased NT-proBNP levels at 1 yr
1 yr: 2.7%/
11.3% (for HF)
Continued on the next page
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Table 2 Continued
First Author (Ref. #)
Drug
Duration
(months) n
Systolic
Function
Diastolic Function
as Inclusion Criterion Positive Outcomes
Mortality/
Readmission
Kitzman et al. (19)
Enalapril
12 71 LVEF 50% Not determined None
Deswal et al. (26)
Eplerenone
6 44 LVEF 50% Not determined Reduced collagen turnover circulating biomarkers
Decreased E/e’
6 months: 0%/
6.8% (for HF)
Conraads et al. (29)
Nebivolol
6 116 LVEF>45%
LVEDD<3.2cc/m2
or LVEDVI
<102 ml/m2
E/e’ >15 or E/e’: 8–15 if:
E/A <0.5 DT >280 ms
None
Solomon et al. (31)
Neprilysin
3 301 LVEF 45% Not determined NT-proBNP reduced 3 months: 1%/
3.3% (for HF)
Yamamoto et al. (30)
Carvedilol
38 245 LVEF >40% Not determined None 38 months:
25.7%
mortality þ
HF admission
Edelmann et al. (27)
Aldosterone
13 422 LVEF 50% Grade 1 E/e’ declined at 6 months and maintained at 12 months
LVEDD and LVM index decreased
Redﬁeld et al. (28)
Sildenaﬁl
6 216 LVEF 50% Not determined None
Other Types of Trials
Kitzman et al. (32)
Aerobic exercise
4 53 LVEF 50% Not determined Improved exercise capacity (VO2peak, workload, exercise time) and submaximal
exercise performance (VAT, 6MWT). Increased HRpeak, HRR, O2 pulse.
Improved physical score of MLHFQ
Edelmann et al. (33)
Aerobic and anaerobic
exercise
3 64 LVEF 50% Grade 1 Improved exercise capacity (VO2peak, workload, exercise time) and submaximal
exercise performance (VAT, 6MWT). Improved E/e’. Decreased LAVI. Improved
SF-36 and MLHFQ scores. Reduced procollagen type 1 blood levels
Smart et al. (34) Aerobic
exercise
4 30 LVEF >45% Delayed relaxation or pseudonormal
ﬁlling pattern
Increased exercise capacity (VO2peak, workload). Increased CO. Improved strain
rate, SV, and CO, in patients with >10% increase in VO2peak
Haykowsky et al. (35)
Aerobic exercise
4 40 LVEF 50% Not determined Improved exercise capacity (VO2peak). Increased HRpeak, HRR. Increased
estimated peak and reserve A-VO2 Diff and peak and reserve circulatory
power
Fujimoto et al. (36)
Aerobic exercise
12 20 LVEF >50% Not determined Improved E/A
Kitzman et al. (37) 4 63 LVEF 50% Not determined Improved exercise capacity (VO2peak, workload, exercise time) and submaximal
exercise performance (VAT, 6MWT). increased HRpeak, Improved SF-36 score
6MWT ¼ 6-min walk test; ACEI ¼ angiotensin-converting enzyme inhibitor; ARRV ¼ age-related reference value; A-VO2 Diff ¼ arterial-venous oxygen difference; CO ¼ cardiac output; DT ¼ deceleration time; edv ¼ end-diastolic volumes; Em ¼ peak early diastolic velocity;
HRpeak ¼ peak heart rate; HRR ¼ heart rate reserve; IQR ¼ interquartile range; IVRT ¼ isovolumic relaxation time; LAD ¼ left atrial diameter; LAVI ¼ left ventricular atrial volume; LV ¼ left ventricular; LVED ¼ left ventricular end-diastolic; LVEDD ¼ left ventricular end-diastolic
diameter; LVEDVI ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; LVM ¼ left ventricular mass; LVWMI ¼ left ventricular wall motion index; LVWT ¼ left ventricular wall thickness; MAD ¼ mitral atrial
duration; MI ¼ myocardial infarction; MLHFQ ¼ Minnesota Living with Heart Failure Questionnaire; mPAP ¼ mean pulmonary artery pressure; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; PCWP ¼ pulmonary capillary wedge
pressure; PVARD ¼ pulmonary vein atrial reversal duration; PVARV ¼ pulmonary vein systolic diastolic velocity; PVS/DV ¼ pulmonary vein systolic/diastolic velocity; SF-36 ¼ 36-Item Short Form Health Survey; Sm ¼ peak systolic velocity; SR ¼ strain rate; VAT ¼ ventilatory
anaerobic threshold; VE/VCO2 ¼ ventilatory equivalent for carbon dioxide; VO2peak ¼ peak oxygen consumption; VO2AT ¼ oxygen consumption at anaerobic threshold.
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Table 3 Potential Phase II Clinical Trial Targets
Parameters
Left ventricle
Systolic function
Ejection fraction Systolic time intervals
Regional myocardial velocities,
strain, systolic strain rate
Isovolumic contraction time
dP/dt Noninvasive single-beat end-systolic
elastance
End-systolic pressure/volume
ratio
End-systolic stress–velocity of
circumferential ﬁber shortening
relation
Stroke work Pre-load recruitable stroke work
Diastolic function
E wave velocity E/A ratio
E wave deceleration time Pulmonary venous ﬂow
Color M-mode velocity of
propagation
E’
E/e’ ratio Noninvasive single-beat end-
systolic elastance
End-diastolic pressure/end-
diastolic volume
End-diastolic pressure/stroke
volume
Early diastolic strain rate
Structure
Left ventricular end-systolic
volume index
Left ventricular end-diastolic volume
index
Left ventricular mass index Extracellular volume fraction
Relative wall thickness LV mass/volume ratio
Left atrium
Left atrial volume/index (LAVI) Left atrial strain
A velocity a’ velocity
Left atrial function/index (LAFI)
Hemodynamics
Right heart catheterization
Pulmonary capillary wedge
pressure
Pulmonary artery pressure
Pulmonary vascular resistance Transpulmonary gradient
(mPAP-PCWP)
Pulmonary vascular gradient
(PADP-PCWP)
Echocardiogram-derived
Pulmonary capillary wedge
pressure approximation by E/e’
Mean pulmonary artery pressure
by end-diastolic pulmonary
regurgitation gradient
Systolic pulmonary artery
pressure by tricuspid
regurgitation gradient
Pulmonary vascular resistance
approximation by TR velocity/
TVIRVOT ratio or RVSP-E/e’/
RVOT VTI
Continued in the next column
Table 3 Continued
Vascular and endothelial function
Central pulse pressure Pulse wave velocity
Flow mediated dilation Reactive hyperemia index
Augmentation index
Exercise capacity
Walking tests
6-min walk test Shuttle walking test
Cardiopulmonary exercise test
VO2max VO2 at anaerobic threshold
VE/VCO2 Exercise oscillatory breathing (EOB)
Biomarkers
Cardiac load and wall stress
Natriuretic peptides
Cardiac ﬁbrosis and collagen turnover
Procollagen type I N-terminal
pro-peptides
Procollagen type III N-terminal pro-
peptides
Matrix metalloproteinases Tissue inhibitors of matrix
metalloproteinases
b-galactoside-binding protein
Galectin-3
Inﬂammation
Growth differentiation factor-15 High-sensitivity C-reactive protein
Interleukins
Myocardial injury
High-sensitivity troponin T
LV ¼ left ventricular; mPAP ¼mean pulmonary artery pressure; PADP ¼ pulmonary artery diastolic
pressure; PCWP ¼ pulmonary capillary wedge pressure; RVOT ¼ right ventricular outﬂow tract;
RVSP ¼ right ventricular systolic pressure; TR ¼ tricuspid regurgitation; TVIRVOT ¼ right ventricular
outﬂow tract time-velocity integral; VE/VCO2 ¼ ventilatory equivalent ratio for carbon dioxide;
VO2 ¼ oxygen consumption; VO2max ¼ maximum oxygen consumption.
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104admissions compared with HFrEF (63). In these patients,
30% of mortality is noncardiovascular, underscoring the
importance of comorbidities.
Whether HFpEF simply represents a collection of com-
orbidities has been questioned. Campbell et al. (9) compared
mortality in HFpEF patients with similar age, sex, and co-
morbidity distribution to patients enrolled in other cardio-
vascular trials. Striking differences were found in mortality
between non-HFpEF patients (11 to 47 per 1,000 patient-
years) and HFpEF mortality rate (53 to 76 per 1,000
patient-years) patients, suggesting that HFpEF risk goes
beyond that explained by age and comorbidities. A recentpaper suggested that both the cardiac and vascular abnor-
malities seen in HFpEF may be related to an underlying
milieu of systemic inﬂammation that is related to the
combination of various comorbidities seen commonly in
HFpEF patients (67).
Therapeutic Targets and Endpoints
Phase II trials. There are many structural and functional
targets that may be amenable to novel interventions. Further
research is needed to assess the magnitude and the time
frame of change in these targets, and how they relate to
clinical outcomes (Table 3, Fig. 1).
LEFT VENTRICLE AND LEFT ATRIUM. Multiple LV and LA
parameters predict outcomes (Table 4) (51,52,68–71).
Diastolic dysfunction, increased LV mass, mass/volume
ratio, LA area, diastolic wall stress, and e’ that is relatively
pre-load independent predict outcomes. One may target the
fundamental cellular and molecular signaling pathways that
result in increased LV distensibility and improve relaxation,
recoil, and ﬁlling, and diastolic function. The best way of
measuring LV diastolic function to assess therapy remains
to be clariﬁed, but may include assessing relaxation, untwist,
suction, stiffness, distensibility, compliance, elastance, and
ventriculoarterial coupling. Other potential parameters
include volume, mass, wall thickness, LVEF, E/e’ ratio,
e’ velocity, and longitudinal strain. Diffuse ﬁbrosis is
Figure 1 Potential Therapeutic Targets in HFpEF
HFpEF ¼ heart failure with preserved ejection fraction.
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105prognostically important (72,73). Dynamic measures of LV
function may be normal at rest but become abnormal during
exercise. The role of exercise in improving surrogate markers
of LV function in clinical trials needs studying. Changes in
LA size may integrate extent and duration of increased dia-
stolic pressure and changes related to diastolic dysfunction,
mitral regurgitation, and atrial ﬁbrillation. Magnetic reso-
nance imaging, tissue Doppler techniques including trans-
mitral ﬂow (A velocity) and longitudinal velocity of the mitral
annulus attributable to LA systolic function (tissue Doppler a’
velocity), and speckle-tracking echocardiography can provide
insight through analysis of regional and global LV and LA
function. A comprehensive list of variable for patients with
HFpEF is presented in Figure 2.
HEMODYNAMICS. HF is characterized by altered hemody-
namics. Detailed analysis of contractility, relaxation, and
volumes require methods such as conductance catheters,
which show impaired adaptation including blunted increase
in stroke volume with heart rate in HFpEF (74). Exercise
during hemodynamic assessment may unmask HFpEF (45).
Data in acute HFpEF are limited. Increases in intracardiac
pressures occur days before the onset of clinical signs and
symptoms. Information from an implanted pulmonary artery
pressure sensor was associated with a 30% reduction in
HF hospitalization at 6 months and 38% per year; 23% of
participants had HFpEF in this study (75). Continuoushemodynamic monitoring-based management strategy (76)
showed a nonsigniﬁcant 21% reduction in HF hospitaliza-
tions; 25% of participants had HFpEF.
VASCULAR AND ENDOTHELIAL FUNCTION. Higher pulse
pressure is seen in HFpEF (77). Increased pulse wave velocity
and augmentation index are associated with systolic and
diastolic dysfunction. Impaired ﬂow-mediated dilation and
changes in peripheral artery tonometry are associated with
worse outcomes in HF (78).
BIOMARKERS. Collagen expression is increased in HFpEF
and increases in collagen-related biomarkers are associated
with hypertrophy and diastolic dysfunction. The associa-
tion between galectin-3 and the risk of mortality and read-
mission is stronger in HFpEF than HFrEF (79). In animal
models, galectin-3 was causally implicated in the HFpEF
pathophysiology, suggesting galectin-3 as a possible target.
Inhibition of galectin-3 is associated with attenuation of
diastolic dysfunction and LV ﬁbrosis (80). Several other
collagen-related biomarkers correlate with higher risk (81).
Other biomarkers that reﬂect different mechanisms and
may be useful in HFpEF include growth differentiation
factor-15, ST2, and cardiac troponins.
Natriuretic peptides (NPs) are lower in HFpEF, and
many patients have B-type NP levels of <100 pg/ml (82).
Irbesartan is associated with improved outcomes in patients
Table 4 Echocardiographic Changes, Biomarkers, and Prognosis of Heart Failure With Preserved Ejection Fraction
Marker (Method) First Author ( Ref. #) Population Outcome
Predictive Properties
HR (95% CI)
E/A (severity of DD)
(echocardiography)
Persson et al. (51) 293 HF patients with LVEF
>40% participating in
CHARMES
Composite CV mortality
or HF admission
Moderate or severe DD
3.27 (1.41–7.56)*
e’ (echocardiography) Wang et al. (71) 174 hypertensive individuals
with LVH
Cardiac mortality 0.49 (0.32–0.76)y
LV massz (echocardiography) Zile et al. (52) 745 HF patients with
LVEF 45% participating
in I-PRESERVE
All-cause mortality or
hospitalization for worsening
HF, MI, stroke, unstable angina,
or ventricular or atrial
dysrhythmia
1.019 (1.009–1.029)x
LV mass/volume
(echocardiography)
1.296 (1.074–1.564) x
Enlarged LAjj (echocardiography) 1.470 (1.029–2.101) x
LAD{ (echocardiography) Rossi et al. (69) 183 HF patients with
LVEF >45%
All-cause mortality 2.45 (1.12–5.41)#
Diastolic wall stress**
(echocardiography)
Ohtani et al. (70) 327 HF patients with
LVEF 50%
Composite CV mortality or
HF admission
1.03 (1.01–1.06)yy
Natriuretic peptides
(blood sample analysis)
Grewal et al. (68) 181 HF patients with LVEF
>40% participating in
CHARMES
Composite CV mortality or
HF admission or MI or stroke
NT-proBNP >300 pg/ml
5.8 (1.3–26.4)
NT-proBNP >600 pg/ml
8.0 (2.6–24.8)
BNP >100 pg/ml
3.1 (1.2–8.2)
*After adjustment for age, sex, left ventricular ejection fraction (LVEF), diabetes mellitus, atrial ﬁbrillation, previous heart failure (HF) admission, and treatment arm. yAfter adjustment for age, and
interventricular septal thickness in diastole, LVEF, peak velocity during systole, peak velocity during late diastole, peak E-wave velocity to peak velocity during early diastole ratio (E/Em), and pseudonormal
diastolic ﬁlling pattern or restrictive diastolic ﬁlling pattern. zIndexed to height2.7. xAfter adjustment for log N-terminal pro–B-type natriuretic peptide (NT-proBNP), age, diabetes mellitus, hospitalization for
worsening HF within 6 months preceding randomization, chronic obstructive pulmonary disease or asthma, neutrophils, and LVEF. jjMildly enlarged left atrium (LA) if LA area was 20 to 30 cm2 and
moderately to severely enlarged LA if LA area was >31 cm2. {LA diameter >5 cm used to deﬁne LA enlargement. #After adjustment for clinical and echocardiographic parameters. **Diastolic wall stress
was deﬁned as the ratio of the posterior wall thickness at end-systole minus the posterior wall thickness at end-diastole to the posterior wall thickness at end-systole. yyAfter adjustment for age, sex,
echocardiographic variables, and log B-type natriuretic peptide (BNP).
CHARMES ¼ CHARM Echocardiographic Substudy; CI ¼ conﬁdence interval; CV ¼ cardiovascular; DD ¼ diastolic dysfunction; HR ¼ hazard ratio; I-PRESERVE ¼ Irbesartan in Heart Failure With Preserved
Systolic Function; LVH ¼ left ventricular hypertrophy; MI; myocardial infarction.
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106with NP levels below but not above the median (83). The
role of NP as a marker of potential responders is being
investigated. In the PARAMOUNT trial, N-terminal pro–
B-type NP was reduced more with LCZ696 than valsartan
(31). NP may be normal or near normal in symptomatic
HFpEF patients but indicate poor outcome once elevated.
Selection of patients on the basis of elevated NP may
identify a cohort with higher risk, and lowering NPs may be
a target. This needs to be studied, however, because patients
with elevated NP levels may have advanced HFpEF with
ﬁbrosis and/or atrial ﬁbrillation, which will make the
myocardium less responsive to intervention.
EXERCISE CAPACITY. Exercise training studies show that the
improved arterial-venous oxygen difference after exercise
may be responsible for the improved exercise capacity. The
exact underlining mechanisms for this are uncertain, and
improved peripheral vascular microvascular function and/or
increased oxygen utilization has been proposed. Skeletal
muscles can be relatively rapidly rejuvenated and represent a
possible target for interventions. Symptom limited exercise
tests offer important information about the maximum ex-
ercise capacity whereas submaximal tests provide informa-
tion about the ability to independently complete daily
activities. In the Ex-DHF (Exercise training in Diastolic
Heart Failure) pilot trial, 3 months of exercise training
improved exercise capacity in HFpEF (33).
COMORBIDITIES. Important targets for HFpEF treatment
include comorbidities. The beneﬁts of treating hypertensionand coronary disease are known. Treatment with continuous
positive airway pressure may reverse diastolic dysfunction in
sleep apnea (84). Maintaining sinus rhythm, and if not
possible then rate control, is important. Catheter ablation
of atrial ﬁbrillation improves diastolic function (85). Renal
denervation has shown promise in animal models, but spe-
ciﬁc human HFpEF data are lacking. Treatment of car-
diometabolic diseases also represents potential targets.
Phase III trials. Mortality and hospitalization rates remain
important targets; however, most patients with HFpEF are
elderly and many will die of conditions other than HF.
Improving symptoms and maintaining independence and
exercise capacity are important for this population. A novel
endpoint focusing on the “patient journey” should be
developed and tested.
The goals for HFpEF treatment remain only partially
understood. These patients are generally older and the
competing risk for death is substantial. Targeting HFpEF-
related abnormalities may improve physiology and patient
status but not mortality. Due to increased HF readmission
scrutiny, care is increasingly being shifted to other venues.
Also, the determinants of quality of life in general depend on
issues larger than any speciﬁc disease process, and data in
this regard are problematic (e.g., patients using tobacco
report better quality of life [86] deﬁbrillators may worsen
quality of life but improve survival, and inotropes improve
symptoms but worsen mortality). Though all of these remain
important endpoints, considering their limitations, there is a
need to develop new endpoints. The common HFpEF
Figure 2 Comprehensive Echocardiographic Phenotypic Analysis of Heart Failure With Preserved Ejection Fraction
Comprehensive echocardiography, including 2-dimensional, Doppler, tissue Doppler, and speckle tracking, allows for detailed phenotypic analysis of cardiac structure, function,
and mechanics in patients with heart failure with preserved ejection fraction. The ﬁgure shows examples of information that can be obtained from the apical 4-chamber (A4C)
view. Clockwise from the top: speckle-tracking echocardiography for assessment of left ventricular (LV) regional and global longitudinal strain (early diastolic strain rate can also
be obtained in this view). Mitral inﬂow and tissue Doppler imaging of the septal and lateral mitral annulus provide information on LV diastolic function grade and estimated LV
ﬁlling pressure (E/e’ ratio), along with assessment of longitudinal systolic (s’) and atrial (a’) function. Speckle-tracking analysis of left atrial (LA) function provides peak LA
contractile function (peak negative longitudinal LA strain) and LA reservoir function (peak positive longitudinal LA strain). Tricuspid annular plane systolic function (TAPSE) and
basal right ventricular (RV) free wall peak longitudinal tissue Doppler velocity (RV s’) provide information on longitudinal RV function, as does speckle tracking echocardiography
of the RV (not shown). Finally, analysis of the tricuspid regurgitant jet Doppler proﬁle, when added to the estimated right atrial (RA) pressure, provides an estimate of the PA
systolic pressure. Additional data available from the apical 4-chamber view include assessment of LV volumes and ejection fraction, LA volume, and RV size and global systolic
function (e.g., RV fractional area change). PA ¼ pulmonary artery. Figure courtesy of Sanjiv J. Shah, MD.
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107manifestation includes worsening congestion, requirement to
frequently alter therapy, declining functionality, and end-
organ dysfunction. One may develop an endpoint that is
both related to HF and responsive to changes over time,
acting not as a surrogate for hard outcomes but as an additional
primary outcome. The pertinent domains of such an end-
point may include cardiac structure and function, congestion
and medication status, and functionality. Designing, scoring,
and validating such an endpoint needs further research.
Clinical Trial Protocol Development and Conduct
Careful attention should be focused on clinical trial protocol
development, patient selection, and the trial execution.
Hospitalized HF. Whether patients with dyspnea who
have preserved EF truly have HFpEF in the outpatient
setting is often debated. The criteria used to select patientsin previous trials have varied (Table 5), and most included a
clinical diagnosis and an LVEF above a certain threshold,
which in turn also varied and was arbitrary. In contrast,
hospitalized patients with obvious ﬂuid overload may pro-
vide a more deﬁnitive HFpEF population, who are also at a
signiﬁcantly higher risk. There is a tremendous need to
identify HFpEF treatment in general, but especially in pa-
tients who are hospitalized.
Need for sustained therapies. For the most part, only
transient intravenous therapies have been studied in hospi-
talized patients. Most of these did not improve outcomes,
with the exception of serelaxin. In the RELAX-AHF
(Relaxin in Acute Heart Failure) trial (87), about 45% of
patients had LVEF 40%, hence representing 1 potential
avenue to treat hospitalized HFpEF patients. However,
considering the continued worsening post-discharge out-
comes, oral long-term therapies are needed to improve
Table 5 Inclusion Criteria in Randomized Clinical Trials for Patients With Heart Failure With Preserved Ejection Fraction
First Author (Ref. #) Inclusion Criteria First Author ( Ref. #) Inclusion Criteria
Setaro et al. (20) Not determined etiology
LVEF >45%*
LV peak ﬁlling rate >2.5 edv/s
Aronow and Kronzon (13) Prior MI (>6 months)
LVEF >50%
Aronow et al. (14) Prior MI (>6 months)
LVEF 40%
Hung et al. (21) LVEF >50%
Nodari et al. (22) Mild hypertension
VO2peak 25 ml/kg/min
LVEF  50%
LVEDD <60 mm or <32 mm/m2
E/A <1.0
PCWP rest>12mmHg or exercise>20mmHg
Yusuf et al. (15) LVEF >40%
Bergström et al. (23) LVEF >45%
LVWMI 1.2y
At least 1 of the following:
 E/A < ARRV
 IVRT > ARRV
 E/A normal plus
PVS/DV < ARRV or
PVARD-MAD >20 ms or PVARV > ARRV
Mottram et al. (24) Hypertension requiring antihypertensive
medication and exertional dyspnea
No MI or angina
LVEF >50%
E/A <1
DT >250 m/s
Little et al. (88) LVEF >50% Ahmed et al. (25) In sinus rhythm
LVEF >45%
Cleland et al. (16) At least 2 of the following criteria
 LVEF >40%
 LVWMI: 1.4–1.6
 LAD >25 mm/m2 or >40 mm
 LVWT 12 mm
At least 1 of the following criteria
 E/A <0.5
 Isovolumic relaxation time >105 ms
Massie et al. (17) LVEF 45%
LVH
LAD >46 mm in men and>42 mm in women
Zile et al. (89) LVEF 50% Yip et al. (18) LVEF >45%
Kitzman et al. (19) No other conditions (cardiac/pulmonary/other)
that could mimic HF
LVEF 50%
Kitzman et al. (32) No other conditions (cardiac/pulmonary/other)
that could mimic HF
LVEF 50%
Orozco-Gutierrez et al. (90) LVEF 45%
Fractional shortening 28%
LAD >45 mm
LV septal and posterior thickness >12 mm
Slow, inverted, pseudonormal, or restrictive
pattern of transmitral Doppler ﬂow
Deswal et al. (26) LVEF 50%
BNP 100 pg/ml
Guazzi et al. (91) In sinus rhythm
LVEF 50%
SPAP 40 mm Hg
Desai et al. (92) LVEF 45%
BNP 100 pg/ml or NT-proBNP 360 pg/ml
Conraads et al. (29) LVEF >45%
LVEDD <3.2 cc/m2 or LVEDVI <102 ml/m2
E/e’ >15 or E/e’: 8–15 if:
 E/A <0.5 in patients >50 yrs
 DT >280 ms in patients >50 yrs
 Ard-Ad >30 ms
 LAVI >40 ml/m2
 LVMI>149 g/m2 and>122 g/m in women
Solomon et al. (31) LVEF 45%
NT-proBNP >400 pg/ml
Smart, 2012 (34) LVEF >45%
Delayed relaxation or pseudonormal ﬁlling
Yamamoto et al. (30) LVEF >40%
Edelmann et al. (27) LVEF 50%
Diastolic dysfunction grade 1 or atrial
ﬁbrillation
VO2peak 25 ml/kg/min
Redﬁeld et al. (28) LVEF 50%
LA enlargement
VO2peak 60%z
NT-proBNP 400 pg/ml or
NT-proBNP <400 pg/ml PCWP 20 mm Hg at
rest and >25 mm Hg at exercise
Maurer et al., 2013 (93) LVEF >40%
*Determined by radionuclide ventriculograms. yDetermined as akinesia of  1 segment or hypokinesia of  2 segments , using a 16-segment model with at least 10 segments visible. zBased on the age-
and sex-speciﬁc normal value while respiratory exchange ration is 1.0. Bulleted items indicate where 1 or more diagnostic ﬁndings can be sued to fulﬁll a criterion.
Ard-Ad ¼ reverse pulmonary vein atrial systole ﬂow–mitral valve atrial wave ﬂow; ARRV ¼ age-related reference value; BNP ¼ B-type natriuretic peptide; DT ¼ deceleration time; edv ¼ end-diastolic
volumes; HF ¼ heart failure; IVRT ¼ isovolumic relaxation time; LAD ¼ left atrial diameter; LV ¼ left ventricular; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction;
LVH ¼ left ventricular hypertrophy; LVWMI ¼ left ventricular wall motion index; LVWT ¼ left ventricular wall thickness; MAD ¼mitral atrial duration; MI ¼myocardial infarction; NT-proBNP ¼ N-terminal pro–
B-type natriuretic peptide; PCWP ¼ pulmonary capillary wedge pressure; PVARD ¼ pulmonary vein atrial reversal duration; PVARV ¼ pulmonary vein systolic diastolic velocity; PVS/DV ¼ pulmonary vein
systolic/diastolic velocity; SPAP ¼ pulmonary artery systolic pressure; VO2peak ¼ peak oxygen consumption.
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109outcomes. Length of hospital stay, degree of decongestion
at discharge, changes in standard treatment, and post-
discharge monitoring, all bring additional heterogeneities
that need consideration in trial conduct.
Study population. It is important to identify the drivers of
adverse events in HFpEF. Determining how the risks can be
identiﬁed with routine parameter versus speciﬁc tests (e.g.,
exercise pulmonary pressure measurement), needs study. It
is unclear whether patients with a speciﬁc cause leading to
admission (e.g., hypertensive emergency or tachyarrhythmia)
should be included in trials. Other markers such as wedge
pressure remain ill characterized (e.g., how high does it need
to be at rest or exercise to identify a responder population
and how does its role differ in hospitalized vs. ambulatory
patients). Biomarkers may be helpful, but most have often
been mostly validated in HFrEF and their role may differ
in HFpEF, necessitating better characterization in this
population.
Summary
HFpEF prevalence is increasing, and these patients face
impaired health status and an unabated high risk for adverse
outcomes. The economic burden of HFpEF is substantial. To
date, there is no approved therapy for these patients.To identify
new therapies, a deeper understanding of the subpopula-
tions that ﬁt under the HFpEF umbrella, and more speciﬁc
molecular targets for engagement, are needed. The following
are the summary recommendations from the meeting:
1. There is an urgent need to focus on drug and device
development for HFpEF and clinical, translational,
and basic research should receive a high priority for
support from academia, industry, nongovernmental
organizations, and federal agencies.
2. The diagnostic certainty and the high post-discharge
event rate identify hospitalized HFpEF patients as a
particularly important HFpEF population.
3. Currently, there are no animal models that sufﬁ-
ciently approximate the HFpEF syndrome to allow
drug and device testing before application to human
studies. Research to develop relevant animal models
is needed.
4. The lack of animal models should not, however,
prevent human testing of promising therapies. To
promote fundamental understanding, animal models
of HFpEF should be developed alongside attempts
to understand better the clinical phenotypes of
HFpEF.
5. There is a need to characterize HFpEF further to
understand better clinical manifestations, contribu-
tion of comorbidities, and mechanisms. This may aid
development of objective classiﬁcation of HFpEF.
Developing longitudinal registries focused on col-
lecting clinical, imaging, laboratory, treatment pat-
terns and outcomes data may facilitate this.6. There are many potential cardiovascular structural
and functional targets for phase II trials. However,
their responsiveness to change and correlation with
phase III outcomes are not known. All phase II
HFpEF studies should consider incorporating a set
of cardiovascular structural and functional parame-
ters, biomarkers, and functional capacity indicators
to improve our understanding of the basic mecha-
nisms of the disease. Currently, there is no consensus
in this regard, necessitating the need for a dialogue
between academia, industry, and regulators.
7. Though many mechanisms for the development and
progression of HFpEF are cited (e.g., endothelial
dysfunction), data for them are sparse, underscoring
the need for further human mechanistic studies.
8. Further data are needed to understand the differ-
ences between hospitalized and stable outpatients
with HFpEF, and the triggers for decompensation,
to develop new therapies.
9. Novel phase III outcome measures that supplement
mortality and hospitalization risk, and incorporate
features reﬂective of the “patient journey” with
HFpEF longitudinally, should be developed.
10. Careful patient selection and a focus on safety in
drug development are important considerations in
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